Clinical trialNCT03921879UnknownPhase 1Interventional

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

SponsorOncotartis, Inc.Enrollment50LymphomaLymphoma, B-CellLymphoma, FollicularLymphoma, HodgkinLymphoma, Non-HodgkinLymphoma, Peripheral T-Cell+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study will test OT-82, which is an investigational ("research" or "experimental" ) drug. The study has two stages (Stage 1 and Stage 2). The purpose of Stage 1 is to determine the safety and tolerability and the maximum tolerated dose (MTD) or the maximum tested dose of OT-82 administered orally to participants. The purpose of Stage 2 is to determine the preliminary efficacy of OT-82 in relapsed or refractory lymphoma at the MTD or the maximum tested dose. Both parts of the study will also evaluate the pharmacokinetics (absorption, distribution, metabolism, elimination) of OT-82. OT-82 treatment slowed the growth, reduced the size, or in some cases cured certain cancers in animal studies. It is hoped that participants with relapsed or refractory lymphoma treated with OT - 82 in this study will experience slowing tumor growth and/or reduction of tumor size.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eric Rowinsky, MD
Oncotartis, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
City of Hope National Medical Center
Duarte, California, United States
Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Roswell Park Cancer Institute
Buffalo, New York, United States
Recruiting
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OT-82 Dose EscalationOT-82 Dose Expansion

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Jul 2019
Primary completion: 30 Apr 2021
Completion: 30 Jun 2021
Last update posted: 23 Oct 2020
Registered enrollment: 50
Registry id: NCT03921879

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.